The Global Transdermal Patch Market is Expected to Reach $20 Billion by 2028 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2028” report has been added to ResearchAndMarkets.com’s offering.

The technological advancements in drug delivery have led to innovation of transdermal patches. The transdermal skin patches are articulated to deliver the active ingredients of drugs across skin into the systemic blood circulation in a continued or measured mode through diffusion. Apart from being convenient to patients and non-invasive, transdermal patches offer other advantages such as circumventing first-pass digestion and avoidance of gastric/enzymatic degradation. The transdermal patches are currently being commercialized as hassle-free, convenient, and durable products. These patches can be worn seven days, depending on their therapeutic indication.

The promising response of transdermal patches in the global market has further surged the further research and development in this sector. For instance in 2019, US FDA has approved Secuado, which is the first transdermal patch to treat Schizophrenia. Further in 2021, Gedeon Richter UK has announced that it has become marketing authorization holder (MAH) for Evra, a once weekly contraception for women of fertile age and the only transdermal contraceptive patch licensed in UK. The rising product launches in the global market will have a positive impact on the growth of market.

The pipeline for global transdermal patches is crowded, which suggests positive future of these patches in forthcoming years. For instance, recent clinical trial from Starton Therapeutics showed the promising results of STAR-LLD continuous delivery transdermal patch containing lenalidomide in a non-GLP rabbit pharmacokinetic (PK) and skin irritation study. Moreover, US FDA has also assigned a Prescription Drug User Fee Act target date of March 11, 2022 for the new drug application for Aldarity (donepezil transdermal system) for the treatment of patients with dementia due to mild, moderate, and severe Alzheimer disease. Aldarity is a once weekly transdermal formulation of donepezil that is designed to be worn for 7 days with consistent adhesion. These rising trends will propel the growth of market during the forecast period.

Currently, vaccine segment doesn’t have any transdermal patch showing that this area has lots of untapped opportunities for pharmaceutical companies. Several ongoing clinical trials are evaluating novel vaccine patch for influenza, HIV, COVID-19, and others. Recently in 2022, Institut Pasteur Korea (IPK) announced a research service agreement executed with Juvic Inc. for the joint development of microneedle based influenza vaccines. Merging Juvic’s microneedle production technology and IPK’s vaccine research and development capabilities, this collaboration is expected to facilitate the development of a microneedle influenza vaccine patch. Notably, the microneedle-based vaccine not only reduces the pain dramatically during vaccination but also can be distributed at room-temperature.

The global transdermal patch market is expected to witness high growth rates which is due to presence of key players and established healthcare infrastructure. Further beneficial government initiatives and an increase in the number of research partnerships are also expected to increase the market growth during the forecast period. Besides, high adoption rate of advance technologies is also expected to impel the growth of market in the region. As per our report findings, the global transdermal patch market is expected to surpass US$ 20 Billion by 2028.

Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2028 Report Highlights:

• Research Methodology
• Global & Regional Transdermal Path Market Outlook
• Global Transdermal Patch Market Opportunity > USD 20 Billion
• Clinical Trials Insight By Company, Indication, Drug Molecule & Phase
• Comprehensive Insight On 60 Transdermal Patch Available Commercially
• Comprehensive Insight On 80 Transdermal Patch In Clinical Trials By Phase
• Transdermal Patch Dosage & Price Availability By Indication
• Competitive Landscape

Key Topics Covered:

1. Introduction to Transdermal Patch

2. Transdermal Patches Classification

3. Mechanism of Transdermal Patch Drug Delivery

4. Global Transdermal Patch Market Outlook

5. Global Transdermal Patch Market Trends by Region

6. Transdermal Patches for Cardiovascular Diseases – Market Availability, Dosage & Price Analysis

7. Opioid Drug Containing Transdermal Patches – Market Availability, Dosage & Price Analysis

8. Transdermal Patch in Hormonal Therapy – Market Availability, Dosage & Price Analysis

9. Transdermal Patches for Neurological Disorders – Market Availability, Dosage & Price Analysis

10. Transdermal Patches for Other Conditions – Market Availability, Dosage & Price Analysis

11. Global Transdermal Patch Clinical Pipeline Overview

12. Global Patch Clinical Pipeline By Company, Indication & Phase

13. Marketed Transdermal Patch Clinical Insight

14. Global Transdermal Patch Market Dynamics

15. Global Transdermal Patch Market Future Outlook 2028

16. Competitive Landscape

16.1 3M Pharmaceuticals

16.2 Acrux

16.3 Agile Therapeutics

16.4 Allergan

16.5 ANI Pharmaceuticals

16.6 Antares Pharma

16.7 Bayer HealthCare Pharmaceuticals

16.8 Corium International

16.9 Chase Pharmaceuticals

16.10 DURECT Corporation

16.11 Endo Pharmaceuticals

16.12 Fempharm

16.13 Hisamitsu Pharmaceutical

16.14 Immune Pharmaceuticals

16.15 Imprimis Pharmaceuticals

16.16 Ipsen Bioscience

16.17 Johnson & Johnson

16.18 LaSalle Laboratories

16.19 Lavipharm-increase

16.20 Luye Pharma

16.21 MINRAD International

16.22 NeurogesX

16.23 Noven Pharmaceuticals

16.24 NuPathe

16.25 Nuvo Research

16.26 Novartis

16.27 Pain Therapeutics

16.28 ProStrakan

16.29 Purdue Pharma

16.30 Sanofi

16.31 Scilex Pharmaceuticals

16.32 Senju Pharmaceutical

16.33 Somerset Pharmaceuticals

16.34 Teikoku Seiyaku

16.35 Therapeutic Discovery Corporation

16.36 Transdermal Delivery Solutions Corp

16.37 UCB

16.38 Xel Pharmaceuticals

16.39 Zosano Pharma

For more information about this report visit https://www.researchandmarkets.com/r/p2jupy

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900